Product Description: BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively[1]. BI-671800 has potential for the treatment of poorly controlled asthma[2].
Applications: COVID-19-immunoregulation
Formula: C25H26F3N5O3
References: [1]Boehme SA, et al. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol. 2009 Jan;21(1):81-93./[2]Miller D, et al. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. Allergy Asthma Proc. 2017 Mar 1;38(2):157-164./[3]Lukacs NW, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L767-79.
CAS Number: 1093108-50-9
Molecular Weight: 501.50
Compound Purity: 99.36
Research Area: Inflammation/Immunology; Endocrinology
Solubility: DMSO : 135 mg/mL (ultrasonic)
Target: CRTH2 (GPR44);Prostaglandin Receptor
Deutsch
English
